Cargando…

Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles

Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yu, Xu, Tiantian, Zhao, Mingqi, Hua, Liang, Chen, Yi, Wang, Changbing, Tang, Ying, Zhu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274826/
https://www.ncbi.nlm.nih.gov/pubmed/30428576
http://dx.doi.org/10.3390/ijms19113582
_version_ 1783377697331740672
author Xia, Yu
Xu, Tiantian
Zhao, Mingqi
Hua, Liang
Chen, Yi
Wang, Changbing
Tang, Ying
Zhu, Bing
author_facet Xia, Yu
Xu, Tiantian
Zhao, Mingqi
Hua, Liang
Chen, Yi
Wang, Changbing
Tang, Ying
Zhu, Bing
author_sort Xia, Yu
collection PubMed
description Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. In this study, SeNPs were modified with folic acid (FA), whose receptors were overexpressed on the surface of cancer cells, including human cervical carcinoma HeLa cells, to fabricate tumor-targeting delivery carrier FA-SeNPs nanoparticles. Then, the anticancer drug doxorubicin (DOX) was loaded onto the surface of the FA-SeNPs for improving the antitumor efficacy of DOX in human cervical carcinoma therapy. The chemical structure characterization of FA-Se@DOX showed that DOX was successfully loaded to the surface of FA-SeNPs to prepare FA-Se@DOX nanoparticles. FA-Se@DOX exhibited significant cellular uptake in human cervical carcinoma HeLa cells (folate receptor overexpressing cells) in comparison with lung cancer A549 cells (folate receptor deficiency cells), and entered HeLa cells mainly by the clathrin-mediated endocytosis pathway. Compared to free DOX or Se@DOX at the equivalent dose of DOX, FA-Se@DOX showed obvious activity to inhibit HeLa cells’ proliferation and induce the apoptosis of HeLa cells. More importantly, FA-Se@DOX could specifically accumulate in the tumor site, which contributed to the significant antitumor efficacy of FA-Se@DOX in vivo. Taken together, FA-Se@DOX may be one novel promising drug candidate for human cervical carcinoma therapy.
format Online
Article
Text
id pubmed-6274826
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62748262018-12-15 Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles Xia, Yu Xu, Tiantian Zhao, Mingqi Hua, Liang Chen, Yi Wang, Changbing Tang, Ying Zhu, Bing Int J Mol Sci Article Cancer-specific drug delivery represents an attractive approach to preventing undesirable side effects and increasing the accumulation of the drug in tumors. The surface modification of selenium nanoparticles (SeNPs) with targeting moieties thus represents an effective strategy for cancer therapy. In this study, SeNPs were modified with folic acid (FA), whose receptors were overexpressed on the surface of cancer cells, including human cervical carcinoma HeLa cells, to fabricate tumor-targeting delivery carrier FA-SeNPs nanoparticles. Then, the anticancer drug doxorubicin (DOX) was loaded onto the surface of the FA-SeNPs for improving the antitumor efficacy of DOX in human cervical carcinoma therapy. The chemical structure characterization of FA-Se@DOX showed that DOX was successfully loaded to the surface of FA-SeNPs to prepare FA-Se@DOX nanoparticles. FA-Se@DOX exhibited significant cellular uptake in human cervical carcinoma HeLa cells (folate receptor overexpressing cells) in comparison with lung cancer A549 cells (folate receptor deficiency cells), and entered HeLa cells mainly by the clathrin-mediated endocytosis pathway. Compared to free DOX or Se@DOX at the equivalent dose of DOX, FA-Se@DOX showed obvious activity to inhibit HeLa cells’ proliferation and induce the apoptosis of HeLa cells. More importantly, FA-Se@DOX could specifically accumulate in the tumor site, which contributed to the significant antitumor efficacy of FA-Se@DOX in vivo. Taken together, FA-Se@DOX may be one novel promising drug candidate for human cervical carcinoma therapy. MDPI 2018-11-13 /pmc/articles/PMC6274826/ /pubmed/30428576 http://dx.doi.org/10.3390/ijms19113582 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Xia, Yu
Xu, Tiantian
Zhao, Mingqi
Hua, Liang
Chen, Yi
Wang, Changbing
Tang, Ying
Zhu, Bing
Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title_full Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title_fullStr Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title_full_unstemmed Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title_short Delivery of Doxorubicin for Human Cervical Carcinoma Targeting Therapy by Folic Acid-Modified Selenium Nanoparticles
title_sort delivery of doxorubicin for human cervical carcinoma targeting therapy by folic acid-modified selenium nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274826/
https://www.ncbi.nlm.nih.gov/pubmed/30428576
http://dx.doi.org/10.3390/ijms19113582
work_keys_str_mv AT xiayu deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT xutiantian deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT zhaomingqi deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT hualiang deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT chenyi deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT wangchangbing deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT tangying deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles
AT zhubing deliveryofdoxorubicinforhumancervicalcarcinomatargetingtherapybyfolicacidmodifiedseleniumnanoparticles